Integrated peripheral blood multi-omics profiling identifies immune signatures predictive of neoadjuvant PD-1 blockade efficacy in head and neck squamous cell carcinoma
Integrated peripheral immune profiling enables robust, noninvasive prediction of neoadjuvant PD-1 blockade efficacy in HNSCC. The identified immune cell subsets and plasma biomarkers provide a clinically applicable framework for early response stratification and personalized immunotherapy, supporting liquid biopsy as a viable platform for clinical decision-making. Trial registration Chinese Clinical Trial Registry, clinical trial number CHiCTR2200056354, 04 February 2022, https://www.chictr.org.cn/showproj.html?proj=151364 .
Authors
- Meng Wang (ORCID: https://orcid.org/0000-0002-8002-4672)
- Guojun Han
- W. Wu (ORCID: https://orcid.org/0000-0003-4379-9548)
- Chuanbin Guo (ORCID: https://orcid.org/0000-0001-5810-824X)
- Haoran Zhang (ORCID: https://orcid.org/0000-0002-7929-9003)
- Lin Wang (ORCID: https://orcid.org/0000-0002-5313-5297)
- Jie Zhang (ORCID: https://orcid.org/0000-0003-1587-503X)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- Peking University International Hospital (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-06-21
- DOI
- https://doi.org/10.1186/s12967-025-06770-2
- Citations
- 5
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- Peking University
- Key Technologies Research and Development Program